An open-label titration followed by a randomized, double-blind, placebo-controlled study to assess the efficacy, tolerability, and safety of oxymorphone extended release tablets in opioid-experienced patients with chronic low back pain

Trial Profile

An open-label titration followed by a randomized, double-blind, placebo-controlled study to assess the efficacy, tolerability, and safety of oxymorphone extended release tablets in opioid-experienced patients with chronic low back pain

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2008

At a glance

  • Drugs Oxymorphone (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Aug 2008 Results reported at the 12th World Congress on Pain in August 2008.
    • 22 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top